A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.
The new formulation of Taltz (ixekizumab) 80 mg/mL injection showed significantly reduced injection site pain and an 86% decrease in VAS compared with the original formulation.
Taltz is approved for adults and children with severe plaque psoriasis, adults with active psoriatic arthritis, active ankylosing spondylitis and active non-radiographic axial spondylarthritis.
“Today is an exciting milestone for the nearly 30